Flying Fish Ventures L.P.
13D · may seek influence
new · filed 2025-04-22
Stated purposeThe information set forth in Items 3 and 6 of this Schedule 13D is incorporated by reference in its entirety into this Item 4. The Reporting Persons acquired the securities covered by this Schedule 13D held by them for investment purposes and intend to review their investment in the Issuer on a continuing basis. Subject to the terms of the Shareholder Agreement discussed in Item 6 below, depending on various factors, including but not limited to the Issuer's financial position and strategic direction, price levels of the Ordinary Shares, conditions in the securities markets, and general economic and industry conditions, the Reporting Persons may in the future take actions with respect to their investment in the Issuer as they deem appropriate, including changing their current intentions, w…
Full filing |
84.4% |
new |
2.1bn |
2025-04-22 |
Saint Thomas Commercial S.A.
13D · may seek influence
new · filed 2025-04-22
Stated purposeThe information set forth in Items 3 and 6 of this Schedule 13D is incorporated by reference in its entirety into this Item 4.
The Reporting Persons acquired the securities covered by this Schedule 13D held by them for investment purposes and intend to review their investment in the Issuer on a continuing basis. Subject to the terms of the Shareholder Agreement discussed in Item 6 below, depending on various factors, including but not limited to the Issuer's financial position and strategic direction, price levels of the Ordinary Shares, conditions in the securities markets, and general economic and industry conditions, the Reporting Persons may in the future take actions with respect to their investment in the Issuer as they deem appropriate, including changing their current intentions, …
Full filing |
84.4% |
new |
2.1bn |
2025-04-22 |
Hoche Partners Pharma Holding S.A.
13D · may seek influence
filed 2025-04-16
Stated purposeItem 4 of the Schedule 13D is amended and supplemented as follows:
On April 9, 2025, the Company and Hoche entered into a Subscription and Conversion Agreement pursuant to which Hoche irrevocably elected to convert all of its remaining outstanding obligations under the Note Subscription Agreement into Ordinary Shares and receive the Warrant in connection with such conversion.
The Note Subscription Agreement, originally entered into on November 29, 2024, as amended by that certain Amendment No. 1 dated April 3, 2025, provided for the issuance of Secured Convertible Notes to Hoche in a principal amount of $38,548,333.33. The notes were convertible into Ordinary Shares of the Company, par value $0.01 per share, in accordance with the terms of the Note Subscription Agreement.
Pursuant to th…
Full filing |
84.4% |
|
2.1bn |
2025-04-16 |
Becaril S.A.
13D · may seek influence
new · filed 2025-04-28
Stated purposeThe information set forth under Item 3 is incorporated by reference herein.
On April 9, 2025, the Reporting Person acquired 325,109,560 Ordinary Shares (including shares issuable upon the exercise of a warrant) pursuant to the following transactions:
(A) The Reporting Person acquired 299,560,430 Ordinary Shares for a purchase price per share of $0.06313, pursuant to a Subscription Agreement (the "Subscription Agreement") dated April 3, 2025, by and among the Company, the Reporting Person and Chemo Project, S.A. ("Chemo").
(B) The Reporting Person, in exchange for $362,916.67, acquired (i) $362,916.67 aggregate principal amount of secured convertible notes of the Company and the interest accrued thereunder (the "Notes") from Hoche Partners Pharma Holding S.A. ("Hoche") pursuant to an A…
Full filing |
53.0% |
new |
1.3bn |
2025-04-28 |
Chemo Project, S.A.
13D · may seek influence
new · filed 2025-04-25
Stated purposeThe information set forth under Item 3 is incorporated by reference herein.
On April 9, 2025, the Reporting Person acquired 325,109,560 Ordinary Shares (including shares issuable upon the exercise of a warrant) pursuant to the following transactions:
(A) The Reporting Person acquired 299,560,430 Ordinary Shares for a purchase price per share of $0.06313, pursuant to a Subscription Agreement (the "Subscription Agreement") dated April 3, 2025, by and among the Company, the Reporting Person and Becaril S.A. ("Becaril").
(B) The Reporting Person, in exchange for $362,916.67, acquired (i) $362,916.67 aggregate principal amount of secured convertible notes of the Company and the interest accrued thereunder (the "Notes") from Hoche Partners Pharma Holding S.A. ("Hoche") pursuant to an Assign…
Full filing |
53.0% |
new |
1.3bn |
2025-04-25 |